Gregory T. Went is CEO at Adamas Pharmaceuticals Inc (ADMS). They have made 4 open-market trades across 1 company since 2015, most recently 2019-04-08.
CIK 0001604541
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $50K since 2018, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ADMS | 232,541 | $1.9M |
Shares reported on the most recent Form 4, priced at the 2019-04-10 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ADMS | SELL | 2019-03-20 | 2019-03-21 | $7.99 | $101K | -10.7% | -21.0% | -35.1% |
| ADMS | BUY | 2018-11-07 | 2018-11-08 | $12.98 | $50K | -25.4% | -26.0% | -31.8% |
| ADMS | SELL | 2018-03-21 | 2018-03-22 | $25.75 | $234K | +4.1% | +15.3% | +7.3% |
| ADMS | SELL | 2017-03-21 | 2017-03-22 | $17.03 | $48K | -2.1% | -10.6% | -1.1% |
| ADMS | SELL · 10b5-1 | 2015-05-12 | 2015-05-14 | $18.00 | $49K | -13.8% | +0.8% | +0.8% |
| ADMS | SELL · 10b5-1 | 2015-04-23 | 2015-04-27 | $18.01 | $59K | -13.8% | +0.8% | +0.8% |
| ADMS | SELL · 10b5-1 | 2015-04-20 | 2015-04-22 | $18.00 | $191K | -13.8% | +0.8% | +0.8% |
| ADMS | SELL · 10b5-1 | 2015-04-10 | 2015-04-14 | $7.16 | $106K | -13.8% | +0.8% | +0.8% |
| ADMS | SELL · 10b5-1 | 2015-03-20 | 2015-03-24 | $18.00 | $5K | -13.8% | +0.8% | +0.8% |
| ADMS | SELL · 10b5-1 | 2015-03-17 | 2015-03-19 | $18.00 | $416K | -13.8% | +0.8% | +0.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.